

Vext

(CSE: VEXT and OTCQX: VEXTF)

A growing, profitable operator based in Arizona

Forward Looking Statements



This Presentation contains forward-looking statements that relate to the Company's current expectations and views of future events and should be read together with more detailed information and financial data and statements. This Presentation does not contain all the information you should consider before purchasing securities of Vext Science, Inc. (the "Company" or "Vext"). In some cases, these forward-looking statement can be identified by words or phrases such as "may", "might", "will", "expect", "anticipate", "estimate", "intend", "plan", "indicate", "seek", "believe", "predict" or "likely". Or negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy and financial needs. These forwardlooking statements include, among other, things, statements relating to: the Company's expectations regarding its revenue, expenses and operations; the Company's expectations regarding timing of the completion of the construction and related construction costs; the Company's anticipated cash needs and its needs for additional financing; the Company's intention and ability to grow the business and its operations: including its ability to complete business development and integrate multi-state operations: the Company's expectations regarding harvesting of products and precut sales prices; expectations with respect to future production costs and capacity; expectations regarding our growth rates and growth plans and strategies; expectations with respect to the approval of the Company's cannabis license holders; expectations with respect to the future growth of its

medical and recreational cannabis services with license holders. and any commentary related to the legalization of adult-use, recreational cannabis and the timing related to such legalization, the Company's expected business objectives for the next twelve months. Forward-looking statements are based on certain assumptions and analyses made by the Company considering the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward-looking statements included in this Presentation, the Company has made various material assumptions, including but not limited to (i) obtaining the necessary regulatory approvals; (ii) that regulatory requirements will be maintained; (iii) general business and economic conditions; (iv) the Company's ability to successfully execute its plans and intentions: (v) the availability of financing on reasonable terms: (vi) the Company's ability to attract and retain skilled staff; (vii) market competition; (viii) the products and technology offered by the Company's competitors; and (ix) that our current good relationships with our suppliers, service providers and other third parties will be maintained. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that the actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, prospective purchasers of the Company's securities should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to several

known and unknown risks, uncertainties, assumptions and other factors.

The Company's forward-looking statements are based on the reasonable beliefs, expectations and opinions of management. Although the Company has attempted to identify important factors that could cause actual results to differ materially form those contained in forward-looking statement, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We do not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada.

The Company's common shares (subordinated voting shares) have not been and may never be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any other securities laws. As a result, the common stock may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulations under the U.S. Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws.

Profitable Growth from the Southwest

- Established footprint in Arizona Transitioned to adult-use in early 2021 expected be a \$3 billion market by 2025¹
- Growing presence in Ohio limited license medical market with adult-use upside and a large population
- Pipeline of accretive M&A opportunities set to be a consolidation partner of choice
- Management team with a proven track record of building and operating profitable multi-state manufacturing/distribution footprints – Vext has operated profitably since 2016
- Best-in-class cash flow generation enables Vext to self-fund growth
- Insider alignment with shareholders: ~35.67% ownership²



Vext's Current Footprint

CALIFORNIA - JOINT OPERATION (50%)

- · Fully built-out mfg. facility
- Wholesale Vapen products in market

NEVADA - SERVICE AGREEMENT

- Fully built-out mfg. facility
- Wholesale Vapen products in market

ARIZONA

- Cultivation 20,000 sq. ft. indoor canopy building-out to 58,000 sq. ft.; 10 acres outdoor
- · Fully built-out mfg. facility
- 2 operating dispensaries in Phoenix
- Wholesale Vapen on vast majority of 3rd party dispensary shelves



OHIO - JV (37.5%)

- Cultivator Level I up to 25,000 sq. ft. (~28,000 sq. ft. canopy)
- Fully built-out mfg. facility
- Binding LOI to acquire dispensary in July 2022
- Wholesale Vapen products in market

KENTUCKY CBD - JV (50%)

- Fully built-out mfg. facility
- Wholesale Vapen products in market

OKLAHOMA – JV (25% ownership; 50% economics)

- 10 acres outdoor cultivation
- · Fully built-out mfg. facility
- Wholesale Vapen products in market

Vertically Integrated Footprint in Attractive Arizona Market



CURRENT FOOTPRINT

Arizona – Fully Vertically Integrated







Two Operated **Dispensaries**

20,000 SO. FT of indoor cultivation

Fully built-out manufacturing facility

STRONG FINANCIAL PERFORMANCE^{1,3}

\$34.3M Revenue TTM

45% **Gross Margin**

\$12.4M Adj. EBITDA TTM

36% Adj. EBITDA Margin

TOP TIER OPERATOR

ΔZ

- Vapen brand is one of Arizona's top performers on vast majority of dispensary shelves in the state
- Profitable since 2016²
- Management team with a proven track record of building and operating profitable multi-state manufacturing/ distribution footprints

BEST-IN-CLASS CASH FLOW^{3,4}





Arizona is a growing limited license, adult-use state with a strong fundamental margin profile

- Trailing Twelve Months ended September 30, 2021. Operating Cash Flow (CFO) is defined as Net cash (used in) provided by operating activities, as outlined in the Company's financial statements.
- CFO Margin is defined as CFO divided by Revenue for the TTM period

- "Adjusted EBITDA" and "Adjusted EBITDA Margin" are non-IFRS Financial measures. See Appendix "A" for disclosure pertaining to these terms.
- Based on net profit



Established Retail Distribution

CENTRAL PHOENIX



- 94126 W Indian School Road, Phoenix, Arizona
- Open since August 2013
- Located in the high traffic industrial center of Phoenix.
- 75 parking spots
- Includes additional 3,000 sq. ft. customer waiting area/cafe potential for future expansion

NORTH PHOENIX



- Grand opening on July 10, 2020
- Located near high traffic shopping and business centers
- 95 parking spots



Both operating dispensaries have been optimized for rapid customer service and online ordering. Ample parking has been secured and room to expand on both sites as regulations allow.



One of Arizona's Top Brand Portfolios



VAPEN

- On vast majority of third party dispensary shelves in the state
- Full suite of products Flower, Concentrates, Extracts, Edibles, Beverages, CBD

Broad Arizona distribution enables Vext to partner with brands that want to enter the market Started with beverages to fill gap in portfolio -

WYNK/MAJOR

Started with beverages to fill gap in portfolio began in Q3 2021 - selling well through operated dispensaries and wholesale

Expanding Cultivation Footprint to Fulfill Market Demand in Arizona



CULTIVATION

	Current Canopy	Fully Funded Expansion	Timing
Phoenix	11,000 sf	13,000 sf	Q4 2021
Prescott Valley	9,000 sf	11,000 sf	Q1 2022
Eloy (Phase I)	_	~17,000 sf	Q3 2022
Eloy (Phase II)	-	~17,000 sf	Q3 2023
Total indoor cultivation	20,000 sf	~58,000 sf	
Prescott Valley (Outdoor)	~10 acres		







Focus on Limited License States

	Found	dation	Second leg of g	growth	Example of unlimited lice	ense state
	ARIZONA		оню		COLORADO	
STRUCTURE	Limited License	~	Limited License	~	Unlimited	×
Dispensaries per 100k population	~1.8	~	~0.5	~	~14.1	×
Legalization	Adult Use		Medical		Adult Use	
Population	7.2 Million		11.8 Million		5.8 Million	
Estimated 2022 Sales ¹	\$1.9 Billion		\$525 Million		\$2.6 Billion	

Vext will continue to focus on states with a limited license structure because of their strong margin profiles and protection of sustained returns on invested capital.



Clear Path to Further Growth in Arizona

ARIZONA	Wholesale & Retail	 Expanding the footprints of current dispensaries aligned with new rules Continued opportunity to partner with out-of-state brands to bring them into Arizona
	Cultivation	 20,000 sq. ft. → 41,000 sq. ft. Q3 2022 41,000 sq. ft. → 58,000 sq. ft. Q3 2023 Room for additional expansion
	Manufacturing	 Recently increased manufacturing space by 4x Recently increased kitchen capacity by 3x

Expanding
upstream capacity
and downstream
capabilities in
growing, limited
license states, is a
proven path to
profitable growth

Building a Consolidation Partner of Choice in Limited License States



Limited license, fragmented markets leave small operators without a scalable path forward

Entrepreneurs

 Have difficulty scaling due to a capped number of licenses and lack of access to capital Growing scale and access to capital

Vext Provides

Want to maintain active role in the business


Lean operations which enables current operators to play a role in the larger entity's growth

 Want a combination of cash and stock with room for appreciation **Cash flow positive operations & an attractive stock make a compelling proposition**

Vext solves for the key pain points of today's cannabis entrepreneurs



Quarterly Financial Performance





Share Structure

Subordinated Voting Shares	68,558,624	39.16%
Class A super voting shares post conversion	68,154,000	38.93%
Warrants & Restricted Stock Units (wtd. Avg. exercise price of \$0.76)	35,310,138	20.17%
Options (wtd. Avg. exercise price of \$0.90)	3,064,334	1.75%
Total issued and o/s voting shares* (fully diluted)	175,087,096	100%
Insider ownership		35.67%



*Assuming all super voting shares are converted.

13



Proven Leadership

Management Team

ERIC OFFENBERGER

Chief Executive Officer/COO

Eric Offenberger has been involved in the cannabis sector since 2018, and was appointed Chief Executive Officer of Vext in February 2020. Since that time, he has led growth in the Company's market share, while growing profitability, building a multi-state portfolio and preparing Vext for adult-use legalization in Arizona.

Prior to entering the cannabis industry, Mr. Offenberger spent 30+ years leading organizations in the distribution and manufacturing industries.

He has worked in both large public companies and market leading private organizations. As President and COO of a Steel Service Center he oversaw six divisions with annual revenue of over \$350 million.

Mr. Offenberger has a proven track record growing sales, improving inventory turnover and driving operational efficiencies. He has been involved in green field startups as well as major capital development and installation of enterprise resource planning applications.

Mr. Offenberger holds a bachelors degree in accountancy and CPA certification.

THAI NGUYEN

Executive Chairman/Founder

Thai Nguyen is the Executive Chairman and Founder of Vext Science and the Vapen Brands (Vapen Clear, Vapen Extracts, Vapen Kitchens, & Vapen CBD).

Mr. Nguyen formed Vext to service Herbal Wellness Center. In 2013, he developed the Vapen Brand to be sold retail and wholesale to the other Arizona dispensaries.

Mr. Nguyen has been involved with entrepreneurial ventures in real estate and High Performance Automotive over the past 18 years.

He is a visionary leader in the cannabis industry focusing on trends, relationships and a strong culture.

VAHAN AJAMIAN

Chief Financial Officer and Corporate Secretary

Vahan Ajamian brings more than a decade and a half of capital markets experience to Vext. He was one of the first equity research analysts to cover cannabis companies in North America and was the first analyst to cover the U.S. cannabis sector and U.S. cannabis equities.

Mr. Ajamian has been a consistent expert resource for the broader media on cannabis topics and has been cited by outlets such as CBC, Marijuana Business Daily and BNN Bloomberg, and was named one of the cannabis investment industry's rising stars by Business Insider in 2018.

Mr. Ajamian is a CPA, CA and a CFA® Charterholder.



Proven Leadership

Board of Directors

THAI NGUYEN | EXECUTIVE CHAIRMAN ERIC OFFENBERGER | CEO and COO

DAVID EATON

David Eaton has 35+ years capital markets experience. Consulting to both public and private companies in the areas of investor relations, arranging financings and corporate transactions. Since 2007 he has been Chairman at Baron Global Financial Canada Ltd., a subsidiary of the Hong Kong Stock Exchange Member Firm VBG Group. The firm provides merchant banking services in the areas of financing, transaction planning, corporate transactions, public listings and ongoing public company management.

DR. JONATHAN SHELTON

Dr. Jonathan Shelton is the founder of Brain Fit, LLC a private practice specializing in psychological assessment and evaluation. Dr. Shelton has a Bachelor's degree in Psychology from Howard University in Washington, DC and a Master's and Doctoral degree in Clinical Psychology, Arizona School of Professional Psychology. Independently licensed in the state of Arizona for 5+ years. Focusing on Compensation and Pension Examinations for veterans, Consultative Examinations for the Arizona Department of Disability Determination, and psychological evaluations for the Arizona Department of Child Safety.

MARK W. OPZOOMER

Mr. Opzoomer is an experienced public company director and committee chair. Mr. Opzoomer was the only director to serve the full 12 years of Entertainment One Ltd.'s life as a listed company before its sale to Hasbro Inc. Previous directorships and audit committee chairs include RhythmOne plc, Autonomy Corporation plc, Rambler Media Limited along with Miva Inc and Hodder Headline plc. Previously, he was a non-executive director of Web Reservations International Limited and Newbay Limited, and an adviser to Forward Internet Group, playing a key role in both its acquisition and subsequent disposal of uSwitch at a significant profit. Mark qualified as a Chartered Accountant with PwC (Coopers & Lybrand) in 1981, where he spent 7 years in audit and business investigation services. Mark holds an MBA from IMD, Lausanne, Switzerland, 1987, and earned a Bachelor of Commerce. Honours, from Queen's University, Ontario, Canada, 1979.

Board of Advisors

DR. JEFF YARGER

Dr. Jeff Yarger brings extensive expertise in chemical and pharmaceutical research and development (R&D) to the Vext advisory board as a leading pharmaceutical R&D in both academic and industrial laboratories for over 20 years, and a professor of chemistry, biochemistry and physics at Arizona State University (ASU). Along with Dr. Yarger's extensive R&D and publications in pharmaceuticals, he also has significant active research projects in the areas of biophysical chemistry, nanomaterials and biopolymers, with over 150 publications in top scientific journals.

SCOTT HILL ESQ.

Scott Hill brings over two decades of experience in finance, business and law and is a partner with Sirvent and Hill. He continued his education in Physics and Law at Arizona State University, culminating in a juris doctorate in 1999. Mr. Hill values helping others protect their investments and assets, as evidenced by his law practice's focus on patent law and estate planning. His dedication to superior client communication and outstanding work product prompted him to join WealthCounsel, a collaborative network of more than 1,000 law firms nationwide, in 2006.



- Established footprint in Arizona Transitioned to adult-use in early 2021 expected be a \$3 billion market by 2025¹
- Growing presence in Ohio limited license medical market with adult-use upside and a large population
- Pipeline of accretive M&A opportunities set to be a consolidation partner of choice
- Management team with a proven track record of building and operating profitable multi-state manufacturing/distribution footprints Vext has operated profitably since 2016
- Best-in-class cash flow generation enables Vext to self-fund growth
- Insider alignment with shareholders: ~35.67% ownership²

Appendix A: Non-IFRS Financial Measure



The Company has provided certain non-IFRS financial measures including "Adjusted EBITDA", and "Adjusted EBITDA margin". These non-IFRS financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company defines "Gross margin" as Gross Profit divided by Revenue. The Company defines "Adjusted EBITDA" as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines "Adjusted EBITDA margin" as Adjusted EBITDA divided by Revenue.

The Company has provided these non-IFRS financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental non-IFRS financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. The following tables provide a reconciliation of each of the non-IFRS measures to its closest IFRS measure.

Adjusted EBITDA

The following information provides reconciliations of the supplemental non-IFRS financial measure presented herein to the most directly comparable financial measure calculated and presented in accordance with IFRS.

	Q3 2021	Q3 2020	Q2 2021
Net income after taxes	\$970,106	\$1,412,974	\$1,792,449
Interest (net)	\$75,574	\$63,917	\$(38,194)
Income taxes	\$538,308	-	\$433,636
Depreciation & amortization ¹	\$886,920	\$802,108	\$743,999
EBITDA	\$2,470,908	\$2,278,999	\$2,931,890
Accretion	\$785,192	\$37,542	\$208,946
Share (profit)/loss on JVs	\$2,602	\$76,747	\$102,938
Share-based compensation	\$171,479	\$86,790	\$220,410
Gain on derecognition of ROU	-	-	\$(3,195)
(Gain)/loss on investment	\$212,675	-	
(Gain)/loss on asset disposal	\$(75,000)	\$82,531	-
Foreign exchange	\$(29)	\$18,738	\$2,746
Adjusted EBITDA	\$3,567,827	\$2,581,347	\$3,463,735

^{1.} Includes depreciation reported in cost of sales.

